Quick Info
Status
Currently Recruiting
Estimated Enrollment
12000
Phase
-
Treatment Type
Sample Collection
Trial Type
Observational
Primary Investigator
Andrew Singleton, Ph.D. National Institute on Aging (NIA)
Contact Information
Locations
National Institute of Aging Clinical Research Unit, Baltimore, 21224
Trial Goal
Tests to Expect
Update Notes
No significant updates.
7/8/2019
No significant updates
4/11/2019
No significant updates
1/30/2019
No significant updates
1/5/2019
No significant updates
12/22/2018
No significant updates
12/8/2018
No significant updates
10/26/2018
No significant updates
8/8/2018
No significant updates
5/4/2018
No significant updates
4/25/2018
No significant updates
4/11/2018
No significant updates
4/4/2018
No significant updates
3/23/2018
No significant updates
1/5/2018
No significant updates
9/29/2017
No significant updates
7/11/2017
No significant updates
4/25/2017
No significant updates
4/20/2017
No significant changes
1/24/2017
No significant updates
1/11/2017
No significant updates
11/10/2016
No significant updates
10/26/2016
Description updated
8/31/2016
Recruitment status/Enrollment criteria updated.
11/17/2015
Protocol updated.
10/20/2015
No significant updates.
8/19/2015
Trial has been suspended.
6/1/2015
Enrollment criteria updated.
5/13/2015
No significant updates.
6/25/2014
No significant updates.
3/18/2014
No significant updates.
2/19/2014
Description updated.
1/7/2014
No significant updates.
12/31/2013
New clinical trial added
12/19/2013

Other Information

Purpose
This study aims to further characterize the genetic basis of movement disorders, including ALS.
Eligibility
Both genders, healthy volunteers accepted, 2 years or older.
Details
The objective of this study is to ascertain individuals with a clinical diagnosis of a movement disorder or dementia, their affected and unaffected family members, and unrelated, healthy individuals (to provide control samples); to characterize their phenotypes; and to identify and further characterize genetic contributions to etiology by collecting blood samples, saliva samples, and/or skin biopsies on these individuals for DNA and induced Pluripotent stem (iPs) cell line preparation.
Collaborator(s)
  • National Institutes of Health Clinical Center (CC) ( National Institute on The first aim of this protocol is to collect families with a history of movement disorder in an attempt to clone the causative gene. The second aim of this protocol isAging (NIA) )
News Articles and Summaries
    -
ALS Forum
-
Trial Protocol as Published on Clinicaltrials.gov
NCT02014246 (First Published: 12/12/2013)